血液透析患者血清非对称性与对称性二甲基精氨酸与发病率和死亡率的关系
该研究为血液透析(HEMO)研究的事后分析,纳入1,276例 prevalent 血液透析患者,检测储存样本中ADMA与SDMA水平,采用Cox回归分析其与心脏死亡、心源性猝死、首次心血管事件及全因死亡的关联。结果显示ADMA每翻倍及最高五分位均与上述结局风险升高相关,SDMA的关联在调整ADMA后不再具有统计学显著性。
要点
- ADMA每翻倍与心脏死亡、心源性猝死、首次心血管事件及全因死亡风险升高相关。
- 与最低ADMA五分位(<0.745 μmol/L)相比,最高五分位(≥1.07 μmol/L)上述结局风险更高。
- SDMA与心脏死亡的关联在调整ADMA水平后不再具有统计学显著性。
核心结论
- ADMA以及程度较轻的SDMA与血液透析患者的心血管结局相关。
研究设计与样本
- HEMO研究的事后分析,纳入1,276例随机分组后3至6个月有可用样本的 prevalent 血液透析患者。
- 预测因素为储存样本中测定的ADMA和SDMA水平。
- 采用Cox回归分析,调整人口学特征、临床特征、合并症、白蛋白水平及残余肾功能等潜在混杂因素。
主要发现
- 患者平均年龄57±14(SD)岁,63%为黑人,57%为女性。
- ADMA均值0.9±0.2 μmol/L,SDMA均值4.3±1.4 μmol/L,两者中度相关(r=0.418)。
- 更高的透析剂量或更长的治疗时长与透析前ADMA或SDMA浓度降低无关。
- 完全调整模型中,ADMA每翻倍与心脏死亡(HR 1.83;95% CI 1.29-2.58)、心源性猝死(HR 1.79;95% CI 1.19-2.69)、首次心血管事件(HR 1.50;95% CI 1.20-1.87)及全因死亡(HR 1.44;95% CI 1.13-1.83)风险升高相关。
- 与最低ADMA五分位(<0.745 μmol/L)相比,最高五分位(≥1.07 μmol/L)与心脏死亡(HR 2.10;95% CI 1.44-3.05)、心源性猝死(HR 2.06;95% CI 1.46-2.90)、首次心血管事件(HR 1.75;95% CI 1.35-2.27)及全因死亡(HR 1.56;95% CI 1.21-2.00)风险升高相关。
局限性
- ADMA和SDMA为单时间点测量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Asymmetric (ADMA) and symmetric dimethylarginine (SDMA) are putative uremic toxins that may exert toxicity by a number of mechanisms, including impaired nitric oxide synthesis and generation of reactive oxygen species. The study goal was to determine the association between these metabolites and cardiovascular outcomes in hemodialysis patients. STUDY DESIGN: Post hoc analysis of the Hemodialysis (HEMO) Study. SETTING & PARTICIPANTS: 1,276 prevalent hemodialysis patients with available samples 3 to 6 months after randomization. PREDICTOR: ADMA and SDMA measured in stored specimens. OUTCOMES: Cardiac death, sudden cardiac death, first cardiovascular event, and any-cause death. Association with predictors analyzed using Cox regression adjusted for potential confounders (including demographics, clinical characteristics, comorbid conditions, albumin level, and residual kidney function). RESULTS: Mean age of patients was 57±14 (SD) years, 63% were black, and 57% were women. Mean ADMA (0.9±0.2μmol/L) and SDMA levels (4.3±1.4μmol/L) were moderately correlated (r=0.418). Higher dialysis dose or longer session length were not associated with lower predialysis ADMA or SDMA concentrations. In fully adjusted models, each doubling of ADMA level was associated with higher risk (HR per 2-fold higher concentration; 95% CI) of cardiac death (1.83; 1.29-2.58), sudden cardiac death (1.79; 1.19-2.69), first cardiovascular event (1.50; 1.20-1.87), and any-cause death (1.44; 1.13-1.83). Compared to the lowest ADMA quintile (<0.745 μmol/L), the highest ADMA quintile (≥1.07μmol/L) was associated with higher risk (HR; 95% CI) of cardiac death (2.10; 1.44-3.05), sudden cardiac death (2.06; 1.46-2.90), first cardiovascular event (1.75; 1.35-2.27), and any-cause death (1.56; 1.21-2.00). SDMA level was associated with higher risk for cardiac death (HR, 1.40; 95% CI, 1.03-1.92), but this was no longer statistically significant after adjusting for ADMA level (HR, 1.20; 95% CI, 0.86-1.68). LIMITATIONS: Single time-point measurement of ADMA and SDMA. CONCLUSIONS: ADMA and, to a lesser extent, SDMA levels are associated with cardiovascular outcomes in hemodialysis patients.
引用
- Shafi T, Hostetter TH, Meyer TW, et al. Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients. Am J Kidney Dis. 2017. PMID: 28089476. doi:10.1053/j.ajkd.2016.10.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。